Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma

  • Barbara Stein1,
  • Andres Jan Schrader2,
  • Gerd Wegener3,
  • Christoph Seidel4,
  • Markus A Kuczyk1 and
  • Sandra Steffens1Email author
Contributed equally
BMC Cancer201313:101

DOI: 10.1186/1471-2407-13-101

Received: 15 October 2012

Accepted: 27 February 2013

Published: 6 March 2013

Abstract

Background

To analyse the prognostic significance of preoperative C-reactive protein (CRP) serum level in patients with upper urinary tract urothelial carcinoma (UUT-UC).

Methods

We evaluated 158 UUT-UC patients who had undergone surgery in the University Hospital of Hannover (MHH). 143 (89.4%) suffered from cancer in the renal pelvis, 13 (8.1%) patients presented with tumour located in the ureter. A preoperative CRP value was available for 115 patients. The mean (median) follow-up for these patients was 28.3 (15.1) months.

Results

The median (mean) CRP value of all evaluable patients was 10.0 (40.7) mg/l. The CRP-level, stratified into two subgroups (CRP ≤5 vs. >5 mg/l), correlated significantly with muscle invasive tumour stage (36.4 vs. 78.9%; p<0.001), the risk of presenting nodal disease (4.5 vs. 26.8%; p=0.002) and distant metastasis (2.3 vs. 16.9%; p<0.016). The Kaplan-Meier 5-year cancer specific survival (CSS) rates were 54.2 and 26.4% for patients with preoperative CRP levels ≤ and >5 mg/l, respectively (p<0.006). Next to age and the presence of metastasis, multivariate analysis also identified CRP as a continuous variable as an independent prognosticator for CSS.

Conclusions

A high preoperative serum CRP level is associated with locally advanced and metastatic disease in patients with UUT-UC. Its routine use could allow better risk stratification and risk-adjusted follow-up of UUT-UC patients.

Keywords

UUT-UC Biomarker C-reactive protein Aggressivness Prognosis Survival

Background

Upper urinary tract urothelial carcinoma (UUT-UC) accounts for 5–7% of all urothelial malignancies in adults; and its incidence increased steadily over the last 20 years [1]. Thus UUT-UC, compared to bladder cancer, is still relatively uncommon; however, it is often a highly aggressive tumour and the prognosis, in general, is poorer than that for urothelial cancer of the bladder [1].

As patients' clinical courses vary and are difficult to predict, the stratification of patients to appropriate postoperative surveillance programs and different therapeutic strategies tailored to the individual risk of cancer progression is helpful. Tumour stage, pathological grade, tumour location, lymph node involvement, lymphovascular invasion and surgical procedure are known prognostic factors [26]. However, all of these are postoperative factors, therefore identifying preoperative prognostic factors, including a serum biomarker, would allow a better therapeutic approach. Particularly biomarkers in body fluids could offer the opportunity for more objective and reproducible measurement and risk stratification prior to surgery.

C-reactive Protein (CRP) is an acute phase protein produced almost exclusively by the liver. CRP plasma levels can increase up to 1000-fold in response to microbial infection, trauma, infarction, autoimmune, or malignant diseases. Elevated CRP levels can be a result of an underlying cancer and a premalignant state, respectively, as well as due to tumour growth associated tissue inflammation. A study published in 2009 by Allin et al. [7] involving 10,408 individuals showed that elevated CRP is associated with increased risk of cancer, e.g. lung or colorectal malignancies. Furthermore, an elevated CRP level was associated with an early death, even in patients without metastases [7].

McArdle et al. [8] were able to show that CRP, next to prostate specific antigen (PSA), could serve as an additional independent prognostic marker for tumour-specific survival in metastatic castration-resistant prostate cancer. Furthermore, several studies published in recent years including from 40 up to 1,161 patients indicated that the preoperative CRP level could also be associated with RCC-specific mortality [917].

Concerning urothelial carcinoma, Trichopoulos et al. [18] revealed that elevated CRP can be related to a higher risk of developing bladder cancer. In patients with advanced bladder cancer undergoing chemotherapy elevated CRP levels were shown to be associated with a poor clinical outcome [19]. To our knowledge only one study published so far was able to show that in patients undergoing surgery for UUT-UC an increased CRP level seems to be asscociated with poor survival [20]. Therefore, in this study including 115 patients, we validated the potential pre-operative prognostic significance of CRP in patients undergoing surgery for UUT-UC.

Methods

Patients and tumour characteristics

This study included 158 patients with complete patient and tumour specific characteristics who underwent surgery form 1981–2011 for UUT-UC at the Hannover University Medical Centre (MHH). None of the patients had received preoperative chemotherapy. The regional lymph nodes were dissected in patients with enlarged nodes during surgery or in case of pathological findings on the pre-operative CT scan; an extended lymphadenectomy was not used routinely. 43 patients were excluded because their preoperative CRP levels were unavailable. The ethical committee of the MHH approved the study. The histological tumour subtype was determined according to the 1997 UICC classification. Staging was based on the 2002 TNM classification. Information on patients´ and tumour characteristics, such as age, sex, stage, presence of regional lymph node or distant metastases, histological subtype, tumour grade according to the Who classification, and CRP-value, was obtained from our computerized institutional databases. The pre-operative CRP-value was categorized into two groups CRP≤5 mg/l and >5 mg/l according to the suggestion of Saito et al. [20].

Follow up

After surgery patients underwent urinary cytology and cystoscopy every 3 months for the first 2 years. In addition, CT and/or MRI were used every 6 months for 5 years and annually thereafter. The duration of the follow-up was calculated from date of surgery to the date of death or last follow-up. Death was assessed as either cancer-related or -unrelated. The primary end point of this study was cancer-specific survival (CSS). Information about the exact date as well as cause of death for each patient was received from the patient’s general practitioner, a close family member or the patient’s hospital records if she/he had been followed up or died in our institution. Follow-up assessment ended in October 2011. Until then, all patients’ data were updated at least every 12 months on a regular basis.

Statistical methods

Continuous variables were reported as mean value and standard deviation (SD) or median value and interquartile ranges (IQR) in the case of parametric or non-parametric distribution, respectively. Chi2 and Fisher’s exact tests were conducted to assess correlations of nominal covariate distributions and CRP-groups. The t-test and ANOVA (in case of parametric) or the Mann–Whitney-U-test (in case of non-parametric distribution) was applied to compare metric variables between two or more subgroups.

Receiver operation characteristics (ROC) curves were constructed to assess the potential of preoperative CRP to predict muscle invasive disease, poor differentiation, and the presence of metastasis at the time of surgery.

Kaplan-Meier estimates of survival time were calculated, and subgroups were compared by the log rank test statistic. Multivariate Cox regression models were used to assess the association between survival and CRP-levels adjusted for different clinical and patient covariates (i.e., age, sex, tumour stage and grade, and metastatic status). SPSS 19.0 was used for statistical assessment. In all tests, a two-sided p<0.05 was considered to indicate significance.

Results

Our patient population with an available pre-surgical CRP value consisted of 83 (72.2%) men and 32 (27.8%) women had a mean (median) age of 65.6 (66.8) years (34–90). The median body mass index (BMI) for all patients was 25.0 kg/m2 (IQR, 22.6 – 28.1). 107 (93.9%) suffered from cancer in the renal pelvis, 7 (6.1%) patients presented with tumour located in the ureter. Detailed patients’ and tumour characteristics including stage and grade are summarized in Table 1.
Table 1

Association between different patient and cancer-specific variables with the pre-operative CRP value

Variable

CRP ≤5 mg/l, n (%)

CRP >5 mg/l, n (%)

p-value

Test

Age, mean [years] ±SD

62.8 (±12.2)

67.3 (±11.8)

0.054

t-test

BMI, mean [kg/m2] ±SD

25.7 (±3.8)

25.4 (±4.2)

0.67

t-test

Sex

  

0.67

Fisher

  female

11 (25.0)

21 (29.6)

  

  male

33 (75.0)

50 (70.4)

  

Location

  

0.71

Fisher

  renal pelvis

42 (95.5)

65 (92.9)

  

  ureter

2 (4.5)

5 (7.1)

  

Stage

   

Fisher

  superficial (pT<2)

28 (63.6)

15 (21.1)

<0.001

 

  invasive (≥pT2)

16 (36.4)

56 (78.9)

  

Metastasis 1

  

0.001

Fisher

  N / M -

41 (93.2)

48 (67.6)

  

  N / M +

3 (6.8)

23 (32.4)

  

Grade

  

<0.001

chi-square

  G1

12 (27.3)

7 (9.9)

  

  G2

24 (54.5)

18 (25.4)

  

  G3

8 (18.2)

46 (64.8)

  

1 at time of surgery.

The median / mean follow-up was 15.1 / 28.3 months (IQR, 7.2 – 37.7). By the last day of data acquisition, 39 (33.9%) patients had died from their tumour disease.

Clinical parameters

The mean (median) pre-operative CRP value of all 115 evaluable patients was 40.7 (10.0) mg/l. The mean (median) CRP value in the two subgroups (CRP≤5, n=44 and >5 mg/l, n=71) was 2.3 (2.0) and 64.6 (45.0) mg/l, respectively. Both groups were comparable concerning the distribution of sexes (p=0.67; Fisher’s exact test, Table 1), the BMI value (p=0.67; t-test) and tumour location (p=0.71, Fisher’s exact test; Table 1) as well as age, even though patients with a CRP >5 mg/l tended to be older (p=0.054; t-test).

Tumour-specific parameters

The CRP-level correlated significantly with the tumour stage: 36.4 and 78.9% of all patients with a CRP ≤ and >5 mg/l suffered from muscle invasive disease (pT≥2) at the time diagnosis (p<0.001, Fisher’s exact test). Accordingly, the median CRP value was significantly lower in those patients with superficial compared to invasive cancer (4.0 vs. 19.5 mg/l; p<0.001, Mann–Whitney-U test). The risk of presenting nodal disease (p=0.002, Fisher’s exact test) or distant metastasis (p=0.016, Fisher’s exact test; Table 1) also increased significantly in patients with a CRP value >5 mg/l. Moreover, elevated CRP-levels were found in 9.9, 25.4 and 64.8% of patients with G1, G2 and G3 tumours, respectively (p<0.001, Chi2 test).

Receiver-operating characteristic (ROC) analysis

Applying ROC analyses, the CRP value as a continuous metric variable exhibited an AUC (95% CI) of 0.73 (0.64 – 0.83; p<0.001) for the presence of metastatic disease at the time of surgery (lymph node or visceral metastasis), of 0.76 (0.67 – 0.85; p<0.001) for poor tumour differentiation (G3), and of 0.70 (0.60 – 0.80; p<0.001) for the presence of a muscle invasive stage.

Clinical course and oncological outcome

The median survival for all evaluable patients was 50.1 months (Kaplan-Meier). Applying univariate Cox-Regression calculation, an elevated BMI (p=0.75) or male sex (p=0.11) did not predict CSS. In contrast, T-stage (HR 1.24, 95% CI 1.05-1.48, p=0.014), the presence of metastases at the time of surgery (HR 3.91, 95% CI 1.90-8.04, p>0.001), tumour grade (HR 1.87, 95% CI 1.14-3.07, p=0.013), age in years (HR 1.06, 95% CI 1.03-1.09, p<0.001) and a CRP-value >5 mg/l (HR 2.67, 95% CI 1.28-5.54, p=0.009) were associated with poor CSS. Accordingly, the Kaplan-Meier 5-year CSS rates for patients with a CRP ≤ and > 5 mg/l were 54.2 and 26.4%, respectively (p=0.006, log rank; Figure 1).
https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-13-101/MediaObjects/12885_2012_Article_3750_Fig1_HTML.jpg
Figure 1

Cancer-specific survival (Kaplan-Meier) for all UUT-UC patients plotted against the pre-operative CRP-group. The 5-year survival rates were 54.2 and 26.4%, respectively, for all evaluable patients (n=77) with a CRP of ≤5 mg/l (n=36) and >5 mg/l (n=41), respectively (p=0.006, log rank).

Multivariate analysis including age and CRP as continuous metric parameters as well as sex, tumour stage, and differentiation identified the presence of lymph node and/or distant metastasis at the time of surgery (HR 4.24, 95% CI: 1.89-9.52; p<0.001, Cox regression), age [years] (HR 1.06, 95% CI 1.03-1.10, p<0.001), and the CRP-value [mg/l] (HR 1.01, 95% CI 1.004-1.02, p=0.001) as independent prognosticators for cancer-specific survival in patients with UUT-UC.

Discussion

Only recently, Saito et al. [20] presented a study including 130 patients suggesting for the first time that elevated CRP is associated with a poor prognosis in patients with UUT-UC. The authors recommended stratifying patients according to the CRP cut-off values of 5.0 mg/l. In this study, we could confirm that a CRP value of >5.0 mg/l was significantly associated with muscle invasive disease (pT≥2), lymph node metastasis, distant metastasis and poor tumour differentiation. Furthermore, a high CRP value was associated with poor cancer specific survival in patients undergoing resection for UUT-UC. These results confirmed the impact of circulating CRP levels on the staging and prognosis of patients with UUT-UC.

Saito et al. [20] were able to identify an elevated CRP and lymph node invasion as an independent preoperative risk factor for disease-specific death. In this study multivariate analysis including age, sex, histological subtype, tumour stage, and differentiation identified the presence of lymph node and/or distant metastasis and both an elevated CRP value and age, at least as continuous metric parameters, as independent predictors for CSS in patients with UUT-UC.

As biomarkers in body fluids offer the opportunity for more objective and reproducible measurement prior to tumour surgery, the use of CRP as a worldwide well-standardized parameter, should not be underestimated. Rather than tumour tissue-based factors, it can easily be implemented as a prognostic factor in addition to tumour stage and grade, to more accurately stratify patients with UUT-UC. However, as CRP is a not a specific biomarker its use is limited in patients with other diseases in which CRP might be elevated, e.g. inflammatory or cardiovascular disease.

Systemic inflammatory response is of considerable importance in the relationship between the tumour, the host and outcome in patients with cancer. Elevation of the serum CRP level can be explained as part of a paraneoplastic syndrome [21]. It is likely that the association with muscle invasive disease among patients with high serum CRP levels may be due to tumor spread that cannot be detected either by routine imaging studies or by pathologic examinations.

However, the mechanism of high CRP in patients with solid tumors, e.g. urogential or gastrointestinal cancer, has not been determined yet. Several explanations have been proposed such as that CRP could directly impair immune functions [2224] allowing unrestrained tumour growth. Alternatively, CRP is a component of the acute- phase response mainly induced by interleukin-6, and thus has the potential to enhance or inhibit the proliferation of carcinoma cells. Therefore, an elevated CRP might indicate tumours capable of producing significant amounts of proinflammatory cytokines, in particular interleukin-6 [25, 26].

In genito-urinary malignancies, interleukin-6 functions as an autocrine growth factor for renal cell and prostate cancer [2730]. Previously, we reported that a high preoperative serum CRP level is an independent predictor of poor survival in patients with renal cell cancer [17]. Trichopoulos et al. [18] revealed that elevated CRP can be related to a higher risk of developing bladder cancer. Experimental studies have shown that malignant urothelial cells acquire an additional growth advantage over benign cells by producing interleukin-6 [30]. These findings support the view that a systemic inflammatory response of the host indicates an aggressive nature of UUT-UC.

There are several limitations in our study that need to be acknowledged. The major limitation of this study is its retrospective design therefore the drawn conclusions have to be treated with reservation and need to be confirmed in prospective settings. Further limitations are the relative small number of patients and the short mean follow-up of only 28 month. In addition, surgical series have obvious inherent and selection biases as they only evaluate patients undergoing surgery and patient’s deemed nonsurgical candidates, for metastatic disease or other reasons, are not included. Finally, our cohort included significantly more patients with renal pelvis cancer than with UC of the ureter, this imbalance might have biased our analysis.

Conclusions

This study confirms that a high preoperative CRP-level is significantly associated with muscle invasive and metastatic disease and that CRP can serve as an independent predictor of CSS. Its routine use could allow better risk stratification and risk-adjusted follow-up for patients with upper urinary tract urothelial carcinoma. However, our result should be validated in larger, multicenter studies.

Notes

Declarations

Authors’ Affiliations

(1)
Department of Urology, Hannover Medical School
(2)
Department of Urology, Ulm Medical School
(3)
Cancer Center, Hannover Medical School
(4)
Department of Oncology, Hannover Medical School

References

  1. Munoz JJ, Ellison LM: Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000, 164 (5): 1523-1525. 10.1016/S0022-5347(05)67019-X.View ArticlePubMedGoogle Scholar
  2. Corrado F, Mannini D, Ferri C, Corrado G, Bertoni F, Bacchini P, Lieber MM, Song JM: The prognostic significance of DNA ploidy pattern in transitional cell cancer of the renal pelvis and ureter: continuing follow-up. Eur Urol. 1992, 21 (Suppl 1): 48-50.PubMedGoogle Scholar
  3. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG: Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998, 52 (4): 594-601. 10.1016/S0090-4295(98)00295-7.View ArticlePubMedGoogle Scholar
  4. Kikuchi E, Horiguchi Y, Nakashima J, Hatakeyama N, Matsumoto M, Nishiyama T, Murai M: Lymphovascular invasion independently predicts increased disease specific survival in patients with transitional cell carcinoma of the upper urinary tract. J Urol. 2005, 174 (6): 2120-2123. 10.1097/01.ju.0000181801.22474.8b. discussion 2124View ArticlePubMedGoogle Scholar
  5. Ozsahin M, Zouhair A, Villa S, Storme G, Chauvet B, Taussky D, Gouders D, Ries G, Bontemps P, Coucke PA: Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre Rare Cancer Network study. Eur J Cancer. 1999, 35 (5): 738-743. 10.1016/S0959-8049(99)00012-X.View ArticlePubMedGoogle Scholar
  6. Park S, Hong B, Kim CS, Ahn H: The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. J Urol. 2004, 171 (2 Pt 1): 621-625.View ArticlePubMedGoogle Scholar
  7. Allin KH, Bojesen SE, Nordestgaard BG: Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009, 27 (13): 2217-2224. 10.1200/JCO.2008.19.8440.View ArticlePubMedGoogle Scholar
  8. McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC: Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int. 2006, 77 (2): 127-129. 10.1159/000093905.View ArticlePubMedGoogle Scholar
  9. Iimura Y, Saito K, Fujii Y, Kumagai J, Kawakami S, Komai Y, Yonese J, Fukui I, Kihara K: Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol. 2009, 181 (3): 1004-1012. 10.1016/j.juro.2008.10.156. discussion 1012View ArticlePubMedGoogle Scholar
  10. Kawata N, Nagane Y, Yamaguchi K, Ichinose T, Hirakata H, Takahashi S: How do symptoms have an impact on the prognosis of renal cell carcinoma?. Int J Urol. 2008, 15 (4): 299-303. 10.1111/j.1442-2042.2008.01990.x.View ArticlePubMedGoogle Scholar
  11. Komai Y, Saito K, Sakai K, Morimoto S: Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 2007, 99 (1): 77-80. 10.1111/j.1464-410X.2006.06497.x.View ArticlePubMedGoogle Scholar
  12. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M: Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol. 2006, 13 (11): 1365-1370. 10.1111/j.1442-2042.2006.01563.x.View ArticlePubMedGoogle Scholar
  13. Jabs WJ, Busse M, Kruger S, Jocham D, Steinhoff J, Doehn C: Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int. 2005, 68 (5): 2103-2110. 10.1111/j.1523-1755.2005.00666.x.View ArticlePubMedGoogle Scholar
  14. Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J, Patard JJ: C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer. 2007, 110 (6): 1241-1247. 10.1002/cncr.22896.View ArticlePubMedGoogle Scholar
  15. Lamb GW, McArdle PA, Ramsey S, McNichol AM, Edwards J, Aitchison M, McMillan DC: The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int. 2008, 102 (6): 756-761. 10.1111/j.1464-410X.2008.07666.x.View ArticlePubMedGoogle Scholar
  16. Ramsey S, Lamb GW, Aitchison M, McMillan DC: Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int. 2008, 101 (8): 959-963. 10.1111/j.1464-410X.2007.07363.x.View ArticlePubMedGoogle Scholar
  17. Steffens S, Kohler A, Rudolph R, Eggers H, Seidel C, Janssen M, Wegener G, Schrader M, Kuczyk MA, Schrader AJ: Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer. 2012, 12 (1): 399-10.1186/1471-2407-12-399.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P: Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev. 2006, 15 (2): 381-384. 10.1158/1055-9965.EPI-05-0626.View ArticlePubMedGoogle Scholar
  19. Yoshida S, Saito K, Koga F, Yokoyama M, Kageyama Y, Masuda H, Kobayashi T, Kawakami S, Kihara K: C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int. 2008, 101 (8): 978-981. 10.1111/j.1464-410X.2007.07408.x.View ArticlePubMedGoogle Scholar
  20. Saito K, Kawakami S, Ohtsuka Y, Fujii Y, Masuda H, Kumagai J, Kobayashi T, Kageyama Y, Kihara K: The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 2007, 100 (2): 269-273. 10.1111/j.1464-410X.2007.06934.x.View ArticlePubMedGoogle Scholar
  21. Nakanishi H, Araki N, Kudawara I, Kuratsu S, Matsumine A, Mano M, Naka N, Myoui A, Ueda T, Yoshikawa H: Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma. Int J Cancer. 2002, 99 (2): 167-170. 10.1002/ijc.10343.View ArticlePubMedGoogle Scholar
  22. Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF, McArdle CS: The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2005, 92 (4): 651-654. 10.1038/sj.bjc.6602419.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Du Clos TW, Mold C: C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res. 2004, 30 (3): 261-277. 10.1385/IR:30:3:261.View ArticlePubMedGoogle Scholar
  24. Maccio A, Lai P, Santona MC, Pagliara L, Melis GB, Mantovani G: High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998, 69 (3): 248-252. 10.1006/gyno.1998.4974.View ArticlePubMedGoogle Scholar
  25. Matsumoto K, Kinoshita T, Ishida T, Itoh H, Miki C, Suzuki H: Serum levels of NCC-ST-439 in Dukes' C colorectal cancer patients: a preliminary report. Surg Today. 1999, 29 (1): 91-92. 10.1007/BF02482979.View ArticlePubMedGoogle Scholar
  26. McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC: The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer. 2004, 91 (12): 1993-1995. 10.1038/sj.bjc.6602248.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Borsellino N, Belldegrun A, Bonavida B: Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 1995, 55 (20): 4633-4639.PubMedGoogle Scholar
  28. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T: Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989, 250 (2): 607-610. 10.1016/0014-5793(89)80805-1.View ArticlePubMedGoogle Scholar
  29. Takenawa J, Kaneko Y, Fukumoto M, Fukatsu A, Hirano T, Fukuyama H, Nakayama H, Fujita J, Yoshida O: Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst. 1991, 83 (22): 1668-1672. 10.1093/jnci/83.22.1668.View ArticlePubMedGoogle Scholar
  30. Okamoto M, Hattori K, Oyasu R: Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer. 1997, 72 (1): 149-154. 10.1002/(SICI)1097-0215(19970703)72:1<149::AID-IJC21>3.0.CO;2-D.View ArticlePubMedGoogle Scholar
  31. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/101/prepub

Copyright

© Stein et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.